Braundmeier A G, Fazleabas A T, Lessey B A, Guo H, Toole B P, Nowak R A
University of Illinois, 1207 West Gregory Drive, Urbana, Illinois 61801, USA.
J Clin Endocrinol Metab. 2006 Jun;91(6):2358-65. doi: 10.1210/jc.2005-0601. Epub 2006 Mar 7.
Endometrial remodeling occurs during each menstrual cycle in women and also during the establishment of endometriosis. Both processes involve the production of metalloproteinases (MMPs) by uterine endometrial cells.
The objective of this study was to determine whether tissue remodeling and endometrial invasion involve activation of MMPs by extracellular matrix metalloproteinase inducer (EMMPRIN).
EMMPRIN expression was examined by immunohistochemistry and real-time PCR in ectopic and eutopic endometria. For functional assays, human uterine fibroblasts were treated in the absence or presence of IL-1beta (10 ng/ml) or purified native EMMPRIN (0.5 or 1 microg/ml) for 24 h. Cellular RNA and conditioned medium were assayed by real-time PCR or immunoblotting.
EMMPRIN protein localized to epithelial and fibroblast cells of eutopic and ectopic endometria. The pattern of localization was regulated by ovarian hormones. EMMPRIN mRNA levels varied throughout the menstrual cycle in parallel with the cyclic changes in estradiol. EMMPRIN treatment (0.5 microg/ml) of human uterine fibroblast cells stimulated MMP-1 (5.23-fold) and MMP-2 (8.55-fold), but not MMP-3, mRNA levels over levels in control cells (P < 0.05). EMMPRIN treatment (1 microg/ml) stimulated endogenous EMMPRIN (1.6-fold) mRNA levels (P > 0.05). IL-1beta stimulated MMP-1 (5.6-fold), MMP-2 (2.8-fold), and MMP-3 (75-fold) gene expression, but not EMMPRIN, over levels in control cells (P < 0.05). Both EMMPRIN and IL-1beta treatments stimulated MMP-1, -2, and -3, but not EMMPRIN protein secretion, with 0.5 microg/ml producing the greatest response.
The ability of EMMPRIN to stimulate MMP secretion by endometrial fibroblasts indicates its potential role in uterine remodeling and the pathogenesis of endometriosis.
子宫内膜重塑发生在女性的每个月经周期以及子宫内膜异位症形成过程中。这两个过程都涉及子宫子宫内膜细胞产生金属蛋白酶(MMPs)。
本研究的目的是确定组织重塑和子宫内膜侵袭是否涉及细胞外基质金属蛋白酶诱导剂(EMMPRIN)对MMPs的激活。
通过免疫组织化学和实时PCR检测异位和在位子宫内膜中EMMPRIN的表达。在功能测定中,将人子宫成纤维细胞在不存在或存在IL-1β(10 ng/ml)或纯化的天然EMMPRIN(0.5或1 μg/ml)的情况下处理24小时。通过实时PCR或免疫印迹法检测细胞RNA和条件培养基。
EMMPRIN蛋白定位于在位和异位子宫内膜的上皮细胞和成纤维细胞。定位模式受卵巢激素调节。EMMPRIN mRNA水平在整个月经周期中与雌二醇的周期性变化平行。用EMMPRIN(0.5 μg/ml)处理人子宫成纤维细胞刺激了MMP-1(5.23倍)和MMP-2(8.55倍)的mRNA水平,但未刺激MMP-3,其mRNA水平高于对照细胞(P < 0.05)。用EMMPRIN(1 μg/ml)处理刺激了内源性EMMPRIN(1.6倍)的mRNA水平(P > 0.05)。与对照细胞相比,IL-1β刺激了MMP-1(5.6倍)、MMP-2(2.8倍)和MMP-3(75倍)的基因表达,但未刺激EMMPRIN(P < 0.05)。EMMPRIN和IL-1β处理均刺激了MMP-1、-2和-3,但未刺激EMMPRIN蛋白分泌,0.5 μg/ml产生的反应最大。
EMMPRIN刺激子宫内膜成纤维细胞分泌MMP的能力表明其在子宫重塑和子宫内膜异位症发病机制中的潜在作用。